Evidence map›Paper›PMID 30578081›Full record

ArticleEBioMedicine2019

DNA methylation changes and somatic mutations as tumorigenic events in Lynch syndrome-associated adenomas retaining mismatch repair protein expression.

Satu Mäki-Nevala, Satu Valo, Ari Ristimäki, Virinder Sarhadi, Sakari Knuutila, Minna Nyström, Laura Renkonen-Sinisalo, Anna Lepistö, Jukka-Pekka Mecklin, Päivi Peltomäki

Open access · goldAbstract read
In one paragraph

Article in EBioMedicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Satu Mäki-NevalaDepartment of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland. Electronic address: satu.maki-nevala@helsinki.fi.
Satu ValoDepartment of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.
Ari RistimäkiDepartment of Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Genome-Scale Biology Research Program, Research Programs Unit, University of Helsinki, Finland.
Virinder SarhadiDepartment of Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Sakari KnuutilaDepartment of Pathology, HUSLAB, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Minna NyströmDepartment of Biosciences, University of Helsinki, Helsinki, Finland.
Laura Renkonen-SinisaloDepartment of Surgery, Helsinki University Hospital, Helsinki, Finland.
Anna LepistöDepartment of Surgery, Helsinki University Hospital, Helsinki, Finland.
Jukka-Pekka MecklinSport and Health Sciences, University of Jyväskylä and Jyväskylä Central Hospital, Jyväskylä, Finland.
Päivi PeltomäkiDepartment of Medical and Clinical Genetics, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIHelsinki University Hospital · FIUniversity of Jyväskylä · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDNA mismatch repair (MMR) defects are a major factor in colorectal tumorigenesis in Lynch syndrome (LS) and 15% of sporadic cases. Some adenomas from carriers of inherited MMR gene mutations have intact MMR protein expression implying other mechanisms accelerating tumorigenesis. We determined roles of DNA methylation changes and somatic mutations in cancer-associated genes as tumorigenic events in LS-associated colorectal adenomas with intact MMR.

methodsWe investigated 122 archival colorectal specimens of normal mucosae, adenomas and carcinomas from 57 LS patients. MMR-deficient (MMR-D, n = 49) and MMR-proficient (MMR-P, n = 18) adenomas were of particular interest and were interrogated by methylation-specific multiplex ligation-dependent probe amplification and Ion Torrent sequencing.

findingsPromoter methylation of CpG island methylator phenotype (CIMP)-associated marker genes and selected colorectal cancer (CRC)-associated tumor suppressor genes (TSGs) increased and LINE-1 methylation decreased from normal mucosa to MMR-P adenomas to MMR-D adenomas. Methylation differences were statistically significant when either adenoma group was compared with normal mucosa, but not between MMR-P and MMR-D adenomas. Significantly increased methylation was found in multiple CIMP marker genes (IGF2, NEUROG1, CRABP1, and CDKN2A) and TSGs (SFRP1 and SFRP2) in MMR-P adenomas already. Furthermore, certain CRC-associated somatic mutations, such as KRAS, were prevalent in MMR-P adenomas.

interpretationWe conclude that DNA methylation changes and somatic mutations of cancer-associated genes might serve as an alternative pathway accelerating LS-associated tumorigenesis in the presence of proficient MMR. FUND: Jane and Aatos Erkko Foundation, Academy of Finland, Cancer Foundation Finland, Sigrid Juselius Foundation, and HiLIFE.

Indexed as

DNA MethylationMutationPromoter Regions, GeneticAdultAgedColorectal Neoplasms, Hereditary NonpolyposisDNA Mismatch RepairEpigenesis, GeneticFemaleHumansLong Interspersed Nucleotide ElementsMaleMiddle AgedTumor Suppressor ProteinsTumor Suppressor ProteinsColorectal adenomaDNA methylationDNA mismatch repairLINE-1 methylationLynch syndromeMutationTumorigenesisTumor suppressor

Identifiers

PMID30578081
PMCPMC6355728
OpenAlexW2905457423

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.